The Filing Desk

SI-BONE

SIBN · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

SIBN · Last close · November 13, 2026
$23.44
Value SI-BONE yourself

SI-BONE's revenue rose 20.2% to $201 million in fiscal 2025. Its operating margin was −11.1%, up from −21.1% a year earlier. Free cash flow was −$9 million. The diluted share count rose 3.6%.

SI-BONE, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001459839-26-000036 Updated
Revenue
$201M
20.2%
Operating margin
−11.1%
10.0 pts
Net income
−$19M
 
Free cash flow
−$9M
 
Return on capital
−26.3%
24.6 pts
Market cap
$1.1B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What SI-BONE does

SI-BONE makes medical implants for the pelvis and spine. Its first product, iFuse, is a titanium implant that stabilizes and fuses the sacroiliac joint, where the spine meets the pelvis, to treat pain from dysfunction or degeneration of that joint. The company describes itself as a pioneer of minimally invasive treatment for this condition.

It sells a series of patented titanium implants, the tools used to place them, and implantable bone products. Newer lines, such as iFuse 3D, iFuse TORQ and iFuse Bedrock Granite, are 3D-printed and extend the products to adult spinal deformity and pelvic trauma. Hospitals and surgeons are its customers. It sells mainly through its own sales force and third-party sales agents in the United States, and through its own staff, agents and resellers in other countries.

The company depends heavily on sales of products for sacroiliac joint procedures. It says it competes in a very competitive business and that procedures are shifting from hospitals to ambulatory surgical centers. Its products need US FDA clearance or European CE marking in each market.

Its biggest risks, as it describes them

  • Competing in a very competitive market, with pressure on its prices.
  • Operating losses since it began, with no assurance it will reach profitability.
  • Hospitals and doctors may not get adequate insurer coverage and payment for procedures using its products.
  • Reliance on sacroiliac joint products, which have been most of its sales.
  • Depending on a few suppliers, some with a single source or single location.
From SI-BONE's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

SI-BONE lost money in fiscal 2025: a net loss of $19 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14785156142139
Debt incl. finance leases3535363636
Net debt (negative means net cash)−112−49−120−107−104
Net debt to EBITDA—————
Debt to equity0.3x0.4x0.2x0.2x0.2x
Interest coverage−9.6x−21.1x−13.6x−10.2x−8.5x
Current ratio10.4x6.5x9.0x7.7x8.6x
Quick ratio9.7x5.7x8.2x6.7x7.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project SI-BONE's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of SI-BONE reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 94 of 96 of 9
Rule of 4011.4%6.7%15.7%
Altman Z''1.230.771.52
Accruals ratio−12.7%−8.0%−7.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassFailPass
F-score5 of 94 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put SI-BONE side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
SI-BONEFY2520.2%−11.1%−4.5%−26.3%—6
Establishment Labs HoldingsFY2527.1%−18.5%−27.0%−39.0%—3Compare
AxogenFY2520.2%−3.5%−1.3%−4.9%—5Compare
CerusFY2516.1%−3.7%0.5%———Compare
OrthopediatricsFY2515.4%−16.6%−6.8%−8.2%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue4855677390106139167201
Revenue growth—15.4%21.5%9.0%22.8%18.0%30.5%20.4%20.2%
Gross profit435060648091109132160
Research and development657101214151717
Operating income−17−12−36−39−52−60−47−35−22
Net income−23−18−38−44−57−61−43−31−19
Diluted EPS (US$)−6.65−2.20−1.55−1.50−1.71−1.79−1.13−0.75−0.44
Diluted shares (millions)4825293334384243
Cash flow
Cash from operations−18−14−32−31−40−42−19−12−1
Capital expenditure01236108108
Free cash flow−18−15−34−33−46−51−27−23−9
Dividends paid000000000
Share buybacks000000000
Acquisitions000000000
Stock-based compensation128121723242626
Balance sheet at fiscal year end
Cash and short-term investments221229319614785156142139
Debt incl. finance leases393939403535363636
Total assets36138117223190158230230239
Total liabilities474854545659616461
Shareholders' equity−129906316913498169167178
Margins and ratios
Gross margin89.3%91.3%89.9%87.9%88.4%85.2%78.8%79.0%79.6%
Operating margin−36.2%−21.6%−53.5%−52.5%−57.3%−56.0%−33.8%−21.1%−11.1%
Net margin−48.0%−31.5%−57.1%−59.5%−62.8%−57.6%−31.2%−18.5%−9.4%
Free cash flow margin−37.5%−27.9%−50.6%−45.3%−50.9%−48.1%−19.1%−13.7%−4.5%
Rule of 40 (growth + FCF margin)—−12.5%−29.1%−36.2%−28.1%−30.1%11.4%6.7%15.7%
Return on capital—————−132.1%−75.5%−50.9%−26.3%
Return on equity——−50.1%−37.6%−37.2%−52.6%−32.4%−18.4%−11.0%
Return on assets—−20.0%−30.1%−25.7%−27.4%−35.2%−22.3%−13.4%−8.1%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: SI-BONE's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with SI-BONE.